Samsung Biologics Co.,Ltd. (KRX:207940)

Market Cap	77.22T
Revenue (ttm)	4.55T
Net Income (ttm)	1.08T
Shares Out	71.17M
EPS (ttm)	15,220.67
PE Ratio	71.28
Forward PE	58.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,970
Average Volume	84,484
Open	1,043,000
Previous Close	1,052,000
Day's Range	1,042,000 - 1,086,000
52-Week Range	721,000 - 1,209,000
Beta	0.33
RSI	56.69
Earnings Date	Apr 23, 2025

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 4,770
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 207940

Financial Performance

In 2024, Samsung Biologics's revenue was 4.55 trillion, an increase of 23.08% compared to the previous year's 3.69 trillion. Earnings were 1.08 trillion, an increase of 26.31%.